Evidence map›Paper›PMID 38446568›Full record

Trial reportBlood2024

Germ line genetic NBN variation and predisposition to B-cell acute lymphoblastic leukemia in children.

Carolin S Escherich, Wenan Chen, Yizhen Li, Wenjian Yang, Rina Nishii, Zhenhua Li, Elizabeth A Raetz, Meenakshi Devidas, Gang Wu, Kim E Nichols and 8 more

4 registry-linked trialsOpen access · greenAbstract readClinical Trial
In one paragraph

Trial report in Blood, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00075725 phase3completednot on this map

High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)

TypeinterventionalSponsorChildren's Oncology GroupRan2003 to 2021Enrolled3,154ConditionsAcute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic LeukemiaArmsCyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride
NCT00103285 phase3completednot on this map

Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL)

TypeinterventionalSponsorChildren's Oncology GroupRan2005 to 2021Enrolled5,377ConditionsAcute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic LeukemiaArms3-Dimensional Conformal Radiation Therapy, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride
NCT00137111 phase3completednot on this map

Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

TypeinterventionalSponsorSt. Jude Children's Research HospitalRan2000 to 2014Enrolled501ConditionsLymphoblastic Leukemia, AcuteArmsPrednisone, Dexamethasone, Vincristine, Daunorubicin, Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase, Methotrexate, Cyclophosphamide, Cytarabine, Etoposide, Mercaptopurine, Imatinib, chemotherapy, intrathecal chemotherapy
NCT01225874 nacompletednot on this map

ALinC 17, Classification ©), B-precursor Induction Treatment (I)

TypeinterventionalSponsorChildren's Oncology GroupRan1999Enrolled3,762ConditionsLeukemiaArmsSC-PEG E. coli L-asparaginase, cytarabine, daunorubicin hydrochloride, dexamethasone, methotrexate
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Carolin S EscherichDepartment of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-1402-3647
Wenan ChenDepartment of Pathology, Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN.
Yizhen LiDepartment of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0001-8941-6691
Wenjian YangDepartment of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-7305-5649
Rina NishiiDepartment of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
Zhenhua LiDepartment of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
Elizabeth A RaetzDepartment of Pediatrics and Perlmutter Cancer Center, New York University Langone Health, New York, NY.
Meenakshi DevidasDepartment of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-1099-3478
Gang WuDepartment of Pathology, Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN.
Kim E NicholsDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0002-5581-6555
Hiroto InabaDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
Ching-Hon PuiDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN.ORCID 0000-0003-0303-5658
Sima JehaDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, TN.
Bruce M CamittaDepartment of Pediatrics, Midwest Center for Cancer and Blood Disorders, Medical College of Wisconsin, Milwaukee, WI.
Eric LarsenDepartment of Pediatrics, Maine Children's Cancer Program, Scarborough, ME.
Stephen P HungerDepartment of Pediatrics and Center for Childhood Cancer Research, Children's Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-5492-3957
Mignon L LohDepartment of Pediatrics and the Ben Towne Center for Childhood Cancer Research, Seattle Children's Hospital, University of Washington, Seattle, WA.
Jun J YangDepartment of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN.
St. Jude Children's Research Hospital · USChildren's Hospital of Philadelphia · USMedical College of Wisconsin · USNew England Cancer Specialists · USNYU Langone Health · USSeattle Children's Hospital · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5M
Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Children's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5M
CPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LOH, MIGNON LEE-CHEUN, RELLING, MARY V · 2015 to 2019
$15.1M
Pathogenesis of ETV6-Related Acute Lymphoblastic LeukemiaR01CA241452 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI NICHOLS, KIM ERIKA · 2020 to 2025
$2.6M
JAK inhibition as a novel treatment for hemophagocytic lymphohistiocytosisR21AI113490 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI NICHOLS, KIM ERIKA · 2014 to 2015
$490k
NCI NIH HHS P30 CA021765NCI NIH HHS R01 CA241452NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NIAID NIH HHS R21 AI113490NIGMS NIH HHS P50 GM115279
6 · The paper itself

Abstract

abstractBiallelic mutation in the DNA-damage repair gene NBN is the genetic cause of Nijmegen breakage syndrome, which is associated with predisposition to lymphoid malignancies. Heterozygous carriers of germ line NBN variants may also be at risk for leukemia development, although this is much less characterized. By sequencing 4325 pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL), we systematically examined the frequency of germ line NBN variants and identified 25 unique, putatively damaging NBN coding variants in 50 patients. Compared with the frequency of NBN variants in gnomAD noncancer controls (189 unique, putatively damaging NBN coding variants in 472 of 118 479 individuals), we found significant overrepresentation in pediatric B-ALL (P = .004; odds ratio, 1.8). Most B-ALL-risk variants were missense and cluster within the NBN N-terminal domains. Using 2 functional assays, we verified 14 of 25 variants with severe loss-of-function phenotypes and thus classified these as nonfunctional or partially functional. Finally, we found that germ line NBN variant carriers, all of whom were identified as heterozygous genotypes, showed similar survival outcomes relative to those with wild type status. Taken together, our findings provide novel insights into the genetic predisposition to B-ALL, and the impact of NBN variants on protein function and suggest that heterozygous NBN variant carriers may safely receive B-ALL therapy. These trials were registered at www.clinicaltrials.gov as #NCT01225874, NCT00075725, NCT00103285, NCI-T93-0101D, and NCT00137111.

Indexed as

Cell Cycle ProteinsGenetic Predisposition to DiseaseGerm-Line MutationPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolFemaleHumansInfantMaleNuclear ProteinsCell Cycle ProteinsNBN protein, humanNuclear Proteins

Identifiers

PMID38446568
PMCPMC11443573
OpenAlexW4392519526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.